Ticker Details
CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date:	October 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.13B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.62 | 2.80%
Avg Daily Range (30 D):	$1.64 | 3.09%
Avg Daily Range (90 D):	$1.55 | 2.78%

Institutional Daily Volume
Avg Daily Volume:	1.2M
Avg Daily Volume (30 D):	1.54M
Avg Daily Volume (90 D):	1.76M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	48
Avg Trade Size (Sh.) (90 D):	50

Institutional Trades
Total Institutional Trades:	6,110
Avg Institutional Trade:	$2.98M
Avg Institutional Trade (30 D):	$3M
Avg Institutional Trade (90 D):	$3.58M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.6M
Avg Closing Trade (30 D):	$7.15M
Avg Closing Trade (90 D):	$9.45M
Avg Closing Volume:	88.46K

News

Feb 20, 2026 @ 5:30 PM Is CRISPR Therapeutics Stock Going to $0, or Will ... Source: Prosper Junior Bakiny

Feb 20, 2026 @ 3:22 PM CRISPR Therapeutics Gains After Earnings as Pipeli... Source: Chris Markoch

Feb 13, 2026 @ 8:10 PM The Blastoff-Ready Biotech Stock You'll Kick Yours... Source: Adria Cimino

Feb 13, 2026 @ 6:45 PM CRISPR Therapeutics Spotlights Momentum For Lead G... Source: Vandana Singh

Jan 29, 2026 @ 5:28 PM Forget AI Stocks: This Biotech Could Cure What AI ... Source: Prosper Junior Bakiny

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-6.47	$-1.35	$-6.47
Diluted EPS	$-6.47	$-1.35	$-6.47
Revenue	$3.51M	$.86M	$3.51M
Gross Profit
Net Income / Loss	$-581.6M	$-130.61M	$-581.6M
Operating Income / Loss	$-664.57M	$-154.76M	$-664.57M
Cost of Revenue
Net Cash Flow	$49.21M	$61.06M	$49.21M
PE Ratio